H-Index & Metrics Best Publications

H-Index & Metrics

Discipline name H-index Citations Publications World Ranking National Ranking
Medicine D-index 70 Citations 35,236 341 World Ranking 16003 National Ranking 572

Overview

What is he best known for?

The fields of study he is best known for:

  • Internal medicine
  • Cancer
  • Disease

Luca Richeldi mainly focuses on Idiopathic pulmonary fibrosis, Internal medicine, Immunology, Nintedanib and Intensive care medicine. His Idiopathic pulmonary fibrosis study combines topics from a wide range of disciplines, such as Physical therapy, Surgery, FEV1/FVC ratio and Interstitial lung disease. His study in Interstitial lung disease is interdisciplinary in nature, drawing from both Guideline, Pathology and Lung biopsy.

His work in Internal medicine addresses issues such as Placebo, which are connected to fields such as Gastroenterology and Quality of life. Luca Richeldi interconnects Beryllium Disease, Chemotherapy, Tuberculosis and Berylliosis in the investigation of issues within Immunology. His Intensive care medicine research is multidisciplinary, incorporating elements of International working group, Idiopathic interstitial pneumonia, Evidence-based practice, Disease and Combined pulmonary fibrosis and emphysema.

His most cited work include:

  • An Official ATS/ERS/JRS/ALAT Statement: Idiopathic Pulmonary Fibrosis: Evidence-Based Guidelines for Diagnosis and Management (4402 citations)
  • Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis (2009 citations)
  • An Official American Thoracic Society/European Respiratory Society Statement: Update of the International Multidisciplinary Classification of the Idiopathic Interstitial Pneumonias (1870 citations)

What are the main themes of his work throughout his whole career to date?

Idiopathic pulmonary fibrosis, Internal medicine, Nintedanib, Intensive care medicine and Interstitial lung disease are his primary areas of study. In Idiopathic pulmonary fibrosis, he works on issues like Pathology, which are connected to Lung. His Internal medicine research is multidisciplinary, relying on both Gastroenterology and Placebo.

Luca Richeldi combines subjects such as Disease progression, Oncology, Cardiology and Tolerability, Adverse effect with his study of Nintedanib. His study looks at the relationship between Intensive care medicine and fields such as Disease, as well as how they intersect with chemical problems. His study of Usual interstitial pneumonia is a part of Interstitial lung disease.

He most often published in these fields:

  • Idiopathic pulmonary fibrosis (55.91%)
  • Internal medicine (39.87%)
  • Nintedanib (25.53%)

What were the highlights of his more recent work (between 2019-2021)?

  • Internal medicine (39.87%)
  • Idiopathic pulmonary fibrosis (55.91%)
  • Nintedanib (25.53%)

In recent papers he was focusing on the following fields of study:

Luca Richeldi focuses on Internal medicine, Idiopathic pulmonary fibrosis, Nintedanib, Interstitial lung disease and Lung. His research brings together the fields of Gastroenterology and Internal medicine. The various areas that Luca Richeldi examines in his Idiopathic pulmonary fibrosis study include Clinical trial, Tolerability, FEV1/FVC ratio, Intensive care medicine and Fibrosis.

His FEV1/FVC ratio research focuses on Placebo and how it connects with Exacerbation. His Nintedanib research integrates issues from Pirfenidone and Oncology. Luca Richeldi has included themes like Disease progression, Hypersensitivity pneumonitis and Pathology in his Interstitial lung disease study.

Between 2019 and 2021, his most popular works were:

  • The Role of Chest Imaging in Patient Management during the COVID-19 Pandemic: A Multinational Consensus Statement from the Fleischner Society (550 citations)
  • The Role of Chest Imaging in Patient Management During the COVID-19 Pandemic (171 citations)
  • Nintedanib in patients with progressive fibrosing interstitial lung diseases—subgroup analyses by interstitial lung disease diagnosis in the INBUILD trial: a randomised, double-blind, placebo-controlled, parallel-group trial (55 citations)

In his most recent research, the most cited papers focused on:

  • Internal medicine
  • Cancer
  • Disease

His primary scientific interests are in Idiopathic pulmonary fibrosis, Internal medicine, Coronavirus disease 2019, Pandemic and Intensive care medicine. His study in Idiopathic pulmonary fibrosis focuses on Nintedanib in particular. His work in Nintedanib tackles topics such as Pirfenidone which are related to areas like Gastroenterology, Symptomatic relief, Dermatology and Progressive disease.

His Severe acute respiratory syndrome coronavirus 2 study in the realm of Coronavirus disease 2019 interacts with subjects such as 2019-20 coronavirus outbreak. His Pandemic research incorporates elements of Global health and Severity of illness. The study incorporates disciplines such as Placebo, Tolerability and Idiopathic interstitial pneumonia in addition to FEV1/FVC ratio.

This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.

Best Publications

An Official ATS/ERS/JRS/ALAT Statement: Idiopathic Pulmonary Fibrosis: Evidence-Based Guidelines for Diagnosis and Management

Ganesh Raghu;Harold R. Collard;Jim J. Egan;Fernando J. Martinez.
American Journal of Respiratory and Critical Care Medicine (2011)

6670 Citations

Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis

Luca Richeldi;Roland M. du Bois;Ganesh Raghu;Arata Azuma.
The New England Journal of Medicine (2014)

2810 Citations

An Official American Thoracic Society/European Respiratory Society Statement: Update of the International Multidisciplinary Classification of the Idiopathic Interstitial Pneumonias

William D. Travis;Ulrich Costabel;David M. Hansell;Talmadge E. King.
American Journal of Respiratory and Critical Care Medicine (2013)

2410 Citations

Diagnosis of Idiopathic Pulmonary Fibrosis. An Official ATS/ERS/JRS/ALAT Clinical Practice Guideline.

Ganesh Raghu;Martine Remy-Jardin;Jeffrey L. Myers;Luca Richeldi.
American Journal of Respiratory and Critical Care Medicine (2018)

1126 Citations

Efficacy of a tyrosine kinase inhibitor in idiopathic pulmonary fibrosis.

Luca Richeldi;Ulrich Costabel;Moises Selman;Dong Soon Kim.
The New England Journal of Medicine (2011)

981 Citations

An Official ATS/ERS/JRS/ALAT Clinical Practice Guideline: Treatment of Idiopathic Pulmonary Fibrosis. An Update of the 2011 Clinical Practice Guideline

Ganesh Raghu;Bram Rochwerg;Yuan Zhang;Carlos A. Cuello Garcia.
American Journal of Respiratory and Critical Care Medicine (2015)

873 Citations

The Role of Chest Imaging in Patient Management during the COVID-19 Pandemic: A Multinational Consensus Statement from the Fleischner Society

Geoffrey D. Rubin;Christopher J. Ryerson;Linda B. Haramati;Nicola Sverzellati.
Chest (2020)

836 Citations

Use in routine clinical practice of two commercial blood tests for diagnosis of infection with Mycobacterium tuberculosis: a prospective study

Giovanni Ferrara;Monica Losi;Roberto D'Amico;Pietro Roversi.
The Lancet (2006)

703 Citations

Acute Exacerbation of Idiopathic Pulmonary Fibrosis. An International Working Group Report

Collard Hr;Ryerson Cj;Corte Tj;Jenkins G.
American Journal of Respiratory and Critical Care Medicine (2016)

671 Citations

An official European Respiratory Society/American Thoracic Society research statement: interstitial pneumonia with autoimmune features

Aryeh Fischer;Katerina M. Antoniou;Kevin K. Brown;Jacques Cadranel.
European Respiratory Journal (2015)

531 Citations

If you think any of the details on this page are incorrect, let us know.

Contact us

Best Scientists Citing Luca Richeldi

Toby M. Maher

Toby M. Maher

University of Southern California

Publications: 207

Athol U. Wells

Athol U. Wells

Imperial College London

Publications: 183

Vincent Cottin

Vincent Cottin

Claude Bernard University Lyon 1

Publications: 146

Ganesh Raghu

Ganesh Raghu

University of Washington

Publications: 128

Harold R. Collard

Harold R. Collard

University of California, San Francisco

Publications: 113

Takashi Ogura

Takashi Ogura

University of Hyogo

Publications: 101

Kevin K. Brown

Kevin K. Brown

National Jewish Health

Publications: 86

Demosthenes Bouros

Demosthenes Bouros

National and Kapodistrian University of Athens

Publications: 85

Fernando J. Martinez

Fernando J. Martinez

Cornell University

Publications: 84

Ulrich Costabel

Ulrich Costabel

University of Duisburg-Essen

Publications: 71

Jay H. Ryu

Jay H. Ryu

Mayo Clinic

Publications: 70

Kevin R. Flaherty

Kevin R. Flaherty

University of Michigan–Ann Arbor

Publications: 67

Moisés Selman

Moisés Selman

National Autonomous University of Mexico

Publications: 65

David A. Schwartz

David A. Schwartz

University of Colorado Denver

Publications: 63

Thomas V. Colby

Thomas V. Colby

Mayo Clinic

Publications: 61

Naftali Kaminski

Naftali Kaminski

Yale University

Publications: 58

Something went wrong. Please try again later.